Biomarkers           tested

Commercial Availability

Specimen

Cutoff

Sensitivity

Specificity

NPV

Approval/ Certification

Recommendation by

NCCN

At-home   collection       kit

Total PSA            (tPSA)

Total PSA      (tPSA)

Serum

FDA

Multiple scenarios

Available

tPSA, fPSA,

-2 pro-PSA

Serum

27

31.1%@  Sensitivity    90%

89% for         any          Prostate       cancer

97% for      clinically   significant     Prostate   cancer

FDA



IB and RB

NA

tPSA, fPSA,   intact PSA,hK2

Serum

7.5%

89%

29%

95%

FDA

IB and RB

PCA3

Urine

25

78%

57%

90%

FDA

Exosomal RNA(PCA3,RNA)

ExoDx        Prostate   Intelliscore

Urine

15.6

Initial   Biopsy -   92%

Repeat   Biopsy-   82%

Initial        Biopsy-          91%

Repeat         Biopsy-      92%

FDA

IB and RB

PCA3,     TMPRSS2-ERG     gene fusion,      Serum PSA

Urine,   Serum

CLIA

HOXC6,DLX1,     Serum PSA

Urine,   Serum

PSA <10

89%

53%

95%

CLIA

IB and RB

NA

Sarcosine,        Alanine,            Glycine, and      Glutamate

Urine

CLIA

PSA, Prostate Specific Antigen; PCA3, Prostate Cancer Antigen 3; FDA, Food and Drug Administration; NPV,

Negative Predictive Value; NCCN, National Comprehensive Cancer Network; CLIA, Clinical Laboratory Improvement Amendments,

IB - The clinical decision for the Initial Biopsy; RB - Repeat Biopsy in Prior Negative Biopsy; NA- Not Available

The NCCN has recognized the Prostate Health Index (PHI), 4K Score, ExoDx Intelliscore, My Prostate Score, Select MDx, and ConfirmMDx (a tissue confirmation test).